Introduction
Cyclosporin A (CsA) is an immunomodulatory drug used in the prevention of transplant rejection and in the treatment of auto-immune diseases (1). Classically, it has been reported that CsA exerts its immunomodulatory action via its effect on helper T-lymphocytes by inhibiting interleukin-2 synthesis (2). However, it has recently been described that inhibition of the activation of T-lymphocytes by CsA cannot account adequately for all the effects observed after in vivo administration of the drug (3). Functional modification of the mononuclear phagocyte system cells offers an attractive possibility for explaining the effects of this drug, since these cells participate in an essential way in antigen presentation and, in many cases, they are the final effecters of the immune system. Cyclosporin A has been used successfully in the treatment of advanced interstitial lung diseases (ILD), especially in cases of idiopathic pulmonary fibrosis (IPF) (4) (5) (6) (7) . In this setting, CsA could exert indirect anti-inflammatory effects by inhibiting the production of lymphokines by helper T-cells (8). However, lymphocytes play a minor role in the pathogenesis of IPF; a disease mainly mediated by alveolar macrophages (AMs) and polymophonuclear leukocytes (9). Thus, another possible explanation for the profitable effects of CsA on ILD may be found in its direct anti-inflammatory effect on AMs.
Alveolar macrophages are among the first line of lung defences encountered by pathogens inhaled into the lung (10) and play a role in initiating and maintaining an inflammatory response in the lower respiratory tract (11). In order to participate adequately in the inflammatory response, AMs synthesize and release a large amount of soluble mediators (i.e. hydrolytic enzymes, oxygen free radicals, cytokines, arachidonic acid metabolites) which can injure the lung parenchyma. Specifically, the release of inflammatory cytokines [interleukin -I,8 (IL-l,& tumour necrosis factor-a (TNF-a), IL-6 and IL-81 by AMs (12,13) is a crucial event in the pathogenesis of alveolitis, which is the first stage of diffuse ILD.
The aim of the present study was to investigate the effect of CsA on the secretion of inflammatory cytokines (IL-l/j', TNF-a, IL-6 and IL-8) by human AMs.
Methods

STUDY POPULATION
All patients were informed of the technical aspects of the procedure, and written consent was obtained prior to the None of the subjects smoked and none had been treated for at least 2 months prior to study.
Four subjects as controls, five patients with sarcoidosis, three with hypersensitivity pneumonitis (HP) and five with IPF were studied.
All of the control subjects displayed unexplained dry cough. None of the subjects had radiologic evidence of lung disease or altered lung function measurements. No bronchoscopic anomalies were observed in the pulmonary area in which the BAL was performed. Normal subjects were not included in this study for ethical reasons.
Diagnosis of sarcoidosis was made using the following criteria: compatible clinical history and chest X-ray; lung or peripheral biopsy demonstrating non-caseating epitheloid granulomas with giant cell formation and a co-existing morphology of the parenchyma compatible with sarcoidosis; no history of mycobacterial, fungal or parasitic infections; no history of exposure to inorganic or organic material known to cause granulomatous lung diseases; and abnormal pulmonary functions with either reduced lung volumes or impairment in diffusing capacity. Diagnosis of HP was made on the basis of standard parameters: documented history of exposure to HP antigens; a symptomatic acute episode with chills, fever, cough and breathlessness 448 h after exposure to the specific antigen; radiologic and/or functional features of ILD; serum antibodies against antigens and transbronchial biopsy in agreement with HP.
Diagnosis of IPF required the following: no clinical history of exposure to environmental agents known to cause ILD; no history of chronic lung infections; evidence of interstitial infiltrates on chest X-ray; lung physiology consistent with a restrictive ventilatory defect, including decreased lung volume, normal flow rates, and/or decreased single-breath carbon monoxide diffusion test; and biopsy evidence in each patient of interstitial pneumonitis with varying degrees of interstitial fibrosis without evidence of granulomas, vasculitis or inorganic material visualized by polarized light microscopy. Basal +CsA (2 ngml-') + CsA (20 ng ml -') + CsA (200 ng ml -') +LPS (1Opgmll') +LPS (lOpgmll')+CsA (Olympus BF-10) was passed via the nose to the lower respiratory tract which had been anaesthetized locally. The instrument was wedged in a segmental bronchus of the right middle lobe. A total of 200ml of sterile 0.9% saline solution was instilled, at room temperature, in four aliquots of 50 ml. Fluid was recovered by gentle aspiration with a syringe, taking care to lose none of the liquid. The mixture recovered was collected in a siliconized bottle, previously placed in an ice bath, until later processing (less than 1 h later).
The BAL fluid (BALF) obtained from the patients was quantified and filtered through two layers of sterile surgical gauze. Following this, it was centrifuged at 500 g for 10 min at room temperature and the supernatant was separated from the cell pellet. The latter was washed twice with phosphate-buffered saline solution (PBS; pH 7.4) and the cells were resuspended at a concentration of 1 x lo6 ml -i. Viability, determined by means of trypan blue vital exclusion stain, was >90% in all cases. Total cells were counted in a Neubauer chamber. In each case, several preparations were performed using a cytocentrifuge (Cytospin-2 Shandon), placing 50 000 cells in each cuvette and centrifuging for 7 min at 400 rpm. Using Diff-Quikm and nonspecific esterase-stained preparations, a conventional differential cell count was performed on 200 cells by two independent observers.
ALVEOLAR MACROPHAGE CULTURE
Cells recovered from the BALF were centrifuged for 35 min at 600 g on a Ficoll-Hypaque density gradient (Lymphoprepa, Nyergaard, Oslo, Norway) at 20°C. After interphase separation and two washings with PBS, cells were resuspended in RPM1 1640 (Sigma Chemical Co.) supplemented with 10% heat-inactivated fetal calf serum (Gibco BRL), 2 mM glutamine (Sigma Chemical Co.), 100 U ml ~ '-100 pg ml ~ 1 penicillin-streptomycin (Sigma Chemical Co.) (complete medium). Mononuclear cells (5 x lo5 well-') were plated on culture plates (Costar, Cambridge, MA, U.S.A.) in 2 ml of complete medium and allowed to adhere for 2 h at 37°C in 5% CO,. Non-adhering cells were removed by gentle washing with media, and 2 ml of fresh complete medium was added for further cell culture. Adherent cells (AMs) were incubated alone or with lipopolysaccharide (LPS) (Sigma Chemical Co) (10 pg ml ~ '). CsA (Sandoz, Basel, Switzerland) was added at three in vivo non-toxic concentrations (200, 20 and 2 ng ml -'). After 24 h at 37°C in 5% CO,, the supernatant was collected, centrifuged at 500 g for 10 min and stored at -70°C. None of the three CsA concentrations used modified the viability of cells (assessed by trypan blue exclusion). 
All experiments
were performed using endotoxin-free materials.
CYTOKINE ASSAYS
Interleukin-l/$ TNF-a, IL-6 and IL-8 were measured in AM cell culture supernatants using commercially available enzyme-linked immunosorbent assays (ELISA) (Amersham, U.K.). These ELISA kits consistently detected cytokine concentrations 20.3 pg ml ~ i (IL-l/Z), >4.8 pg ml ~ i (TNF-a), >0.35 pg ml-' (IL-6) and >4.7 pg ml -i (IL-8). All samples were measured in duplicate and the results expressed in pg or ng lo6 AMs. None of the components of the complete culture medium (RPM1 1640, penicillin, streptomycin, L-glutamine or fetal bovine serum) or CsA crossreacted in the ELISA assays.
STATISTICAL ANALYSIS
All data are expressed as means & SEM. For each cytokine, Wilcoxon's signed-rank test for matched pairs was used to compare the differences in cytokine secretion between CsAtreated and untreated AMs; P values ~0.05 were adopted as significant.
Results
The total number of cells recovered and the differential count of recovered cells were similar to the data reported in the literature (data not shown).
Interleukin lp secretion by AMs in the different situations is shown in Table 1 . As expected, LPS stimulation strongly increased IL-lp secretion (P<O.OOl). When AMs were incubated with CsA at lower concentrations (2 ng ml ~ '), the spontaneous release of IL-lfi was not affected while LPSstimulated secretion was inhibited (p=O.O2). At 20 ng ml ~ ', CsA did not modify spontaneous or LPS-stimulated secretion of IL-lb secretion by AMs. However, higher concentrations of CsA (200 ng ml ~ ') increased LPS-stimulated (P=O.O3) secretion of IL-lp (Fig. 1) . Tumour necrosis factor-u secretion by AMs is depicted in Table 2 ). Lipopolysaccharide stimulation strongly increased TNF-a secretion (PcO.001). Spontaneous secretion of TNF-a was not affected by low concentrations of CsA (2 ng ml -'), but this dose decreased LPS-stimulated secretion of TNF-a (P=O.O04). Also, intermediate concentrations of CsA (20 ng ml -') decreased both spontaneous (P=O.OOl) and LPS-stimulated secretion of TNF-a (P=O.O3). Finally, TNF-a levels in untreated and LPSstimulated AM supernatants were decreased by high concentrations (200 ng ml-') of CsA (P<O.OOl) (Fig. 2 ). Interleukin-6 secretion by AMs in the different situations is shown in Table 3 . As expected, LPS stimulation strongly increased IL-6 secretion (P<O.OOl). The addition of low CsA concentrations (2 ng ml -') did not affect spontaneous secretion of IL-6 but decreased LPS-stimulated secretion (P= 0.02). However, at concentrations of 20 or 200 ng ml -i (Fig. 3 ) CsA failed to suppress spontaneous or LPSstimulated IL-6 secretion.
Interleukin-8 secretion by AMs is depicted in Table 4 ). Lipopolysaccharide stimulation strongly increased IL-8 secretion (P<O.OOl). Spontaneous secretion of IL-8 was not affected by low concentrations of CsA (2 ng ml ~ '), but this dose decreased LPS-stimulated secretion of IL-8 (P=O.OOS).
Also, intermediate concentrations of CsA (20 ng ml -') decreased both spontaneous and LPS-stimulated secretion of IL-8 (P~0.05). Finally, IL-8 levels in untreated and LPS-stimulated AM supernatants were decreased by high concentrations of CsA (P<O.Ol) (Fig. 4) .
Discussion
Diffuse pulmonary interstitial diseases, mainly those of unknown aetiology, often generate important therapeutic problems. Although treatment with corticosteroids, combined or not with cytotoxic immunosuppressor agents, is the first step in the management of patients with these diseases, the response to such agents is often reduced or null. Accordingly, in certain specific cases, treatment with CsA has been used empirically to try to modulate the immune and/or inflammatory response underlying most entities included in this group of diseases. However, the rational basis for the use of CsA in such processes is limited. Thus, although this immunomodulator has usually been considered to exert a predominant effect on helper T-lymphocytes, the best response to CsA has been seen in IPF (4-7) a disease mainly mediated by neutrophils and alveolar macrophages.
These results show that CsA produced either no or modest decreases in cytokine production by AMs. At low concentrations (2 ng ml -'), CsA decreased stimulated secretion of all the inflammatory cytokines without affecting spontaneous secretion stimulated secretion of TNF-a and IL-S, without modifying the secretion of IL-l and IL-6. Finally, at high concentrations (200 ng ml -I), CsA increased the stimulated secretion of IL-lp, did not alter that of IL-6 and decreased both the basal and stimulated secretion of TNF-a and IL-8. The inhibition exerted by this immunomodulator on TNF-a and IL-S secretion is concentration dependent. However, only the lowest concentration of CsA (2 ng ml-') was able to inhibit the secretion of IL-6, possibly suggesting that the mechanism of action of CsA on the secretion of this molecule could be different, or that CsA might exert opposite actions on several intracellular processes related to the secretion of IL-6. The increase in the secretion of IL-lp at high CsA concentrations (200 ng ml -') can be explained in terms of the peculiar processing and secretion of this cytokine, which accumulates in the cytoplasm of cells of the mononuclear phagocyte system (14). Since CsA is able to bind to the plasma membrane, modifying its physicochemical properties (15), it would be possible to speculate that at high concentrations (200 ng ml ~ '), this action would elicit an increase in permeability and an increase in release, without altering the synthesis of IL-lj?. The results obtained in this study cannot be compared with those reported in the literature since, after a profound review, the authors found no references to the action of CsA on inflammatory cytokine secretion by human AMs. However, the present results are in agreement with the data relating to the action of CsA on the secretion of IL-l, TNF and IL-6 by other cells of the human mononuclear phagocyte system (16-20). Further and larger studies are needed to confirm these results and to study the mechanism of this CsA action on macrophages.
The second interesting aspect of this study is the demonstration of the CsA effect on the AMs of normal and ILD patients. Accordingly, the drug may be effective in many types of ILD accompanied by macrophage activation. Specifically, these data support the notion of a direct effect of CsA on human AMs as an explanation for the improvement observed in patients with IPF treated with this immunomodulator.
In view of the undebatable role of IL-S in the pathogenesis of IPF (9, 21, 22) and the effect of CsA on the production of IL-S, this immunomodulator could offer a novel and selective approach for future treatment of this type of patients (21) .
The last aspect of interest to emerge from this study is related to the ability of CsA to decrease stimulated secretion of inflammatory cytokines. As systemic administration of CsA did not achieve effective concentrations in the lower respiratory tract (23) it is possible that the administration of the drug through other routes could elicit effective concentrations in the alveolo-interstitial region (23) (24) (25) (26) . In this sense, it should be stressed that current clinical investigations into the use of aerosolized CsA for the treatment of patients undergoing lung transplantation are quite advanced (27, 28) . Additionally, it has been observed that the efficiency of this treatment is correlated with suppression of the production of inflammatory cytokines (29) . As is evident, it would be interesting to study the use of aerosolized CsA for the treatment of ILD. 
